Increased Platelet Glycoprotein IIb/IIIa Activation Precedes Continuous-Flow Left Ventricular Assist Device Pump Thrombosis Events

Continuous-flow left ventricular assist devices (CFLVAD) in management of end-stage heart failure continues to expand. Adverse events however remain high. Better understanding of platelet activation in the context of CFLVAD therapy may help reduce bleeding and pump thrombosis (PT) risks to patients.

Source: The Journal of Heart and Lung Transplantation - March 31, 2020 Category: Transplant Surgery Authors: M. Weiland, J. Schuitema, S. Jovinge, S. Lee Tags: (347) Source Type: research